| Bioactivity | Fosaprepitant (L-785298) is a prodrug of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV)[1]. |
| Target | Neurokinin-1 receptor |
| In Vivo | Fosaprepitant (30 mg/kg; i.p.; daily; for 7 days) attenuates tolerance to morphine and increases the antinociceptive effect in in rats[1]. Animal Model: |
| Name | Fosaprepitant |
| CAS | 172673-20-0 |
| Formula | C23H22F7N4O6P |
| Molar Mass | 614.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pranav Prasoon, et al. Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats. Indian J Pharmacol. 2016 Jul-Aug; 48(4): 394-398. |
Fosaprepitant
CAS: 172673-20-0 F: C23H22F7N4O6P W: 614.41
Fosaprepitant (L-785298) is a prodrug of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, whi
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.